Skip to main content

Table 1 Baseline characteristics of participants

From: Feasibility of remote neurocognitive assessment: pandemic adaptations for a clinical trial, the Cognition and Obstructive Sleep Apnea in Parkinson’s Disease, Effect of Positive Airway Pressure Therapy (COPE-PAP) study

Characteristics

Remote NCT cohort (control or CPAP) (n = 7)

COPE-PAP control cohort (n = 25)

Age, years

60.6 (4.8)

70.6 (10.1)

Sex (M/F)

5/2

16/9

BMI, kg/m2

30.4 (6.8)

29.7 (4.3)

Education, years

16.3 (2.6)

14.4 (3.2)

MoCA test score

23.9 (1.8)

22.4 (3.0)

Epworth Sleepiness Scale score

10.9 (3.0)

10.6 (4.8)

Time from PD diagnosis, years

3.9 (2.2)

9.2 (7.0)

Levodopa equivalent dose, mg/day

374.9 (152.0)

781.9 (446.8)

MDS-UPDRS total score

52.0 (12.2)

64.9 (17.1)

MDS-UPDRS part 1 (non-motor experience of daily living)

12.4 (5.9)

14.2 (4.7)

MDS-UPDRS part 3 (motor examination)

29.1 (7.8)

31.2 (9.8)

Sleep apnea variables

AHI, events/hour

39.8 (11.2)

40.4 (29.7)

ODI, events/hour

14.1 (9.6)

16.3 (18.8)

Mean SpO2

94.3 (1.6)

94.1 (1.9)

Nadir SpO2

86.7 (5.1)

86.2 (7.7)

T90, % TST

1.0 (1.4)

2.5 (4.3)

  1. Results are in mean (standard deviation). AHI, Apnea-hypopnea index, BMI, Body mass index, MDS-UPDRS, Movement Disorder Society- Unified Parkinson’s Disease Rating Scale, MoCA, Montreal Cognitive Assessment, NCT, Neurocognitive testing; ODI, Oxygen desaturation index, RDI, Respiratory disturbance index, T90, % time spent with SpO2 < 90%; TST, Total sleep time